These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 23110469)
1. Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention. Hasan MS; Basri HB; Hin LP; Stanslas J Int J Neurosci; 2013 Mar; 123(3):143-54. PubMed ID: 23110469 [TBL] [Abstract][Full Text] [Related]
2. Clopidogrel pharmacogenetics: metabolism and drug interactions. Close SL Drug Metabol Drug Interact; 2011; 26(2):45-51. PubMed ID: 21819266 [TBL] [Abstract][Full Text] [Related]
3. Interaction between clopidogrel and proton pump inhibitors: hypothesis to explain multifactorial CYP2C19 inhibition. Zhang H; Ragueneau-Majlessi I; Levy RH Drug Metab Lett; 2009 Dec; 3(4):287-9. PubMed ID: 19995331 [TBL] [Abstract][Full Text] [Related]
4. Duration of clopidogrel therapy with drug-eluting stents. Rennings AJ; Schouwenberg BJ; van Onzenoort HA N Engl J Med; 2010 Jul; 363(5):489; author reply 490. PubMed ID: 20830829 [No Abstract] [Full Text] [Related]
5. Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians. Tran M; Tafreshi J; Pai RG J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):326-37. PubMed ID: 20938037 [TBL] [Abstract][Full Text] [Related]
6. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine. Maeda A; Ando H; Asai T; Ishiguro H; Umemoto N; Ohta M; Morishima M; Sumida A; Kobayashi T; Hosohata K; Ushijima K; Fujimura A Clin Pharmacol Ther; 2011 Feb; 89(2):229-33. PubMed ID: 21178986 [TBL] [Abstract][Full Text] [Related]
7. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study. Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612 [TBL] [Abstract][Full Text] [Related]
8. East Asian perspective on the interaction between proton pump inhibitors and clopidogrel. Zou D; Goh KL J Gastroenterol Hepatol; 2017 Jun; 32(6):1152-1159. PubMed ID: 28024166 [TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Giusti B; Gori AM; Marcucci R; Saracini C; Sestini I; Paniccia R; Valente S; Antoniucci D; Abbate R; Gensini GF Pharmacogenet Genomics; 2007 Dec; 17(12):1057-64. PubMed ID: 18004210 [TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population. Subraja K; Dkhar SA; Priyadharsini R; Ravindra BK; Shewade DG; Satheesh S; Sridhar MG; Narayan SK; Adithan C Eur J Clin Pharmacol; 2013 Mar; 69(3):415-22. PubMed ID: 22955794 [TBL] [Abstract][Full Text] [Related]
12. CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China. Jia DM; Chen ZB; Zhang MJ; Yang WJ; Jin JL; Xia YQ; Zhang CL; Shao Y; Chen C; Xu Y Stroke; 2013 Jun; 44(6):1717-9. PubMed ID: 23640828 [TBL] [Abstract][Full Text] [Related]
13. Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes. Nagashima Z; Tsukahara K; Morita S; Endo T; Sugano T; Hibi K; Himeno H; Fukui K; Umemura S; Kimura K J Cardiol; 2013 Sep; 62(3):158-64. PubMed ID: 23886632 [TBL] [Abstract][Full Text] [Related]
14. Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4. Lau WC; Gurbel PA Pharm Res; 2006 Dec; 23(12):2691-708. PubMed ID: 17061171 [TBL] [Abstract][Full Text] [Related]
15. Clopidogrel and genetic testing: is it necessary for everyone? Goswami S; Cheng-Lai A; Nawarskas J Cardiol Rev; 2012; 20(2):96-100. PubMed ID: 22293861 [TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study]. Yasu T; Ikee R; Miyasaka Y; Chubachi H; Saito S Yakugaku Zasshi; 2010 Dec; 130(12):1743-50. PubMed ID: 21139402 [TBL] [Abstract][Full Text] [Related]
17. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. Jeong YH; Tantry US; Kim IS; Koh JS; Kwon TJ; Park Y; Hwang SJ; Bliden KP; Kwak CH; Hwang JY; Gurbel PA Circ Cardiovasc Interv; 2011 Dec; 4(6):585-94. PubMed ID: 22045970 [TBL] [Abstract][Full Text] [Related]
18. [Impact of proton pump inhibitor omeprazole on the antiplatelet effect of clopidogrel in individuals with various CYP2C19*2 genotypes]. Lu FM; Tong ZL; Mao YM; Wu DY; Xu J Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Aug; 29(4):478-81. PubMed ID: 22875511 [TBL] [Abstract][Full Text] [Related]
19. Cytochrome p-450 polymorphisms and response to clopidogrel. Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias W; Braunwald E; Sabatine MS N Engl J Med; 2009 Jan; 360(4):354-62. PubMed ID: 19106084 [TBL] [Abstract][Full Text] [Related]